merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>Lilly's vials are positioned as a safer option than compounded drugs, with FDA approval and quality control</answer>

<question_number>2</question_number>
<answer>LillyDirect offers online prescriptions and direct-to-door delivery, similar to telehealth companies' services</answer>

<question_number>3</question_number>
<answer>Compounded drugs are subject to far less oversight than FDA-approved medications</answer>

<question_number>4</question_number>
<answer>To regain customers who are currently getting compounded tirzepatide</answer>

<question_number>5</question_number>
<answer>When tirzepatide is removed from the shortage list, there should be no space for mass compounders</answer>

<question_number>6</question_number>
<answer>Lilly offers "transparent pricing" by selling directly and removing third-party supply chain entities</answer>

<question_number>7</question_number>
<answer>Older patients on Medicare might seek out the cheaper Zepbound vials, despite potential risks for this age group</answer>

<question_number>8</question_number>
<answer>Lilly positions its vials as a safer, FDA-approved alternative to compounded drugs</answer>

<question_number>9</question_number>
<answer>Tirzepatide is listed as "in shortage" by the FDA</answer>

<question_number>10</question_number>
<answer>Offering lower pricing on Zepbound vials</answer>